Charles River Acquires Blue Stream
News Jun 29, 2016
Blue Stream is an analytical contract research organization (CRO) supporting the development of complex biologics and biosimilars. Located in Woburn, Massachusetts, the company is recognized for its expertise in structural and functional protein characterization programs, and the development and validation of assays for current good manufacturing practice (cGMP) lot release and stability programs. Protein characterization is the key element for development and registration of biologic and biosimilar entities.
James C. Foster, Chairman, President and Chief Executive Officer, said, “Our continued investment in expanding our biologics portfolio, through the development of new assays and capabilities, has enabled us to provide a broader testing solution for our clients. This investment is particularly important now, when the number of biologic and biosimilar drugs in development is increasing. The acquisition of Blue Stream will meaningfully enhance the ability of our Biologic Testing Solutions business to compete effectively in this high-growth market segment.”
Scientists Report The Development of a Potent New Medicine to Fight AddictionNews
Scientists report the development of a potent new medicine to fight addiction.READ MORE
Minoryx Therapeutics spins off SEE-Tx platform into new company, Gain TherapeuticsNews
The new Swiss company will operate in Lugano and Barcelona under the scientific management of Minoryx co-founder Dr Xavier Barril.READ MORE
Evolution Threatens Efficient Bioproduction Scale-UpNews
The transition towards sustainable biobased chemical production is important for green growth, but productivity and yield of engineered cells frequently decrease in large industry-scale fermentation. According to a new study, the role of evolution has been underestimated in limiting bioprocesses.